
Medical Plenary: Hemophilia treatment in 2030
In the Tuesday morning medical plenary, Erik Berntorp describes his vision of hemophilia treatment and medical advances in 2030.
Year: 2025
Language: English
Author(s): World Federation of Hemophilia
Format: Video
This video gives a quick introduction to ultra-long half-life (UHL) clotting factor replacement therapy.
Learn more about different treatment options for hemophilia with the World Federation of Hemophilia Shared Decision Making tool!
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

In the Tuesday morning medical plenary, Erik Berntorp describes his vision of hemophilia treatment and medical advances in 2030.

This eLearning module presents Section 4 of the WFH Guidelines for the Management of Hemophilia: Hemostatic Agents. Detailed illustrations, interactive

This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish Desmopressin (DDAVP) may

Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese This is not an official WFH translation. This resource has been

A summary of discussions held at the Ninth WFH Global Forum on Research and Treatment Products for Bleeding Disorders which